Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories
- Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment
- Agreement includes further product development activities for Clinigen Limited
- Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globally
Munich / London / Athens, March 20th, 2023 - Munich-based pharmaceutical contract development organization (CDMO) Adragos Pharma GmbH has signed a definitive agreement with global pharmaceutical services company Clinigen Limitedto acquire Lamda Laboratories S.A. in Athens. The acquisition of Lamda Laboratories significantly expands Adragos' pharmaceutical product development, regulatory affairs and supply chain management services for its global pharmaceutical customers.
Lamda has not only acted as Clinigen’s sole development center but has also established a well-earned reputation as a highly reliable contract development organization (CDO) for third party customers. Under a pharmaceutical development services agreement, Lamda will continue to provide services for Clinigen Limited.
The Athens site, a mere 15 minute drive from the airport, is fully equipped with state of the art equipment including the handling of potent drugs, established Quality systems and a proven track record of delivering complex developments on time for customers.
A highly experienced management team and well-trained staff will continue to focus on complex product development for growing markets in Europe, Japan, and North America. Lamda will offer an expanded range of pharmaceutical development, regulatory affairs and supply chain management services for a wide range of dosage forms including complex and high potent oral solids, differentiated oral liquids, injectables and topical medicines. As part of the transaction, Adragos secures royalty streams for products stemming from previous co-developments.
David Bryant, Interim CEO of Clinigen Limited states: "We are pleased to have found in Adragos Pharma a trusted partner to build on the success story of Lamda with its great team taking it to the next level while also continuing to support Clinigen as we focus on providing high-value services to the biopharma industry.”
Dr. Andreas Raabe, CEO of Adragos Pharma commended the “impressive track record and professional service mindset at Lamda”. He noted that “Lamda combines differentiated product development capabilities with substantial scale, an essential combination for our international group.”
The exact terms of the transaction will not be disclosed. Completion of the transaction is subject to customary conditions precedent.
About Adragos
Adragos Pharma is a globally operating CDMO with headquarters in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America, and Japan to attain a globally leading position within the next few years and set new standards in customer service and data centricity. In its buy-and-build growth strategy, Adragos Pharma is supported by FSN Capital, a leading Northern European private equity firm, and Prange Group, a diversified leading German family office. Adragos Pharma currently operates four production sites in France, Germany, and Japan.www.adragos-pharma.com
About Clinigen
Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa and the Asia Pacific. Clinigen has more than 1,000 employees across five continents in 15 countries, and provides access in more than 120 countries every year. For more information on Clinigen, please visit: www.clinigengroup.com
Press contact Adragos Pharma
press@adragos-pharma.com
About Adragos Pharma
Adragos Pharma is a globally operating CDMO with headquarters in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America, and Japan to attain a globally leading position within the next few years and set new standards in customer service and data centricity. In its buy-and-build growth strategy, Adragos Pharma is supported by FSN Capital, a leading Northern European private equity firm, and Prange Group, a diversified leading German family office. Adragos Pharma currently operates three production sites in France, Germany, and Japan.
Subscribe to releases from Adragos Pharma
Subscribe to all the latest releases from Adragos Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Adragos Pharma
Successful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan2.3.2023 08:58:15 CET | Press release
Adragos Pharma now third largest pure-play CDMO in the Japanese market Long-term agreement with Sanofi secures local healthcare supply Munich / Paris / Tokyo, March 02, 2023 – Munich-based pharmaceutical contract manufacturer (CDMO) Adragos Pharma GmbH successfully completed the acquisition of one of Japan's leading pharmaceutical manufacturing facilities from Sanofi K.K. The transaction makes Adragos Pharma the third largest pure-play contract manufacturer in Japan, one of its three core markets. The acquisition also kicks off a long-term supply agreement between the CDMO and Sanofi. Kawagoe Pharma will continue to produce for Sanofi and the Japanese market as a strategic partner, thus playing an essential role for the local healthcare system. The official handover of the production facility took place yesterday in the presence of the workforce, which will remain at the site, as well as of representatives of both companies. The Kawagoe site near Tokyo is one of the largest and most te
Adragos Pharma to acquire Sanofi’s manufacturing site in Kawagoe, Japan13.10.2022 10:56:33 CEST | Pressemeddelelse
Munich / Paris / Tokyo, October 13, 2022 – Adragos Pharma, a rapidly growing pharmaceutical Contract Development and Manufacturing Organization (CDMO) based in Munich, Germany, signed definitive agreements with Sanofi K.K. for the acquisition of a pharmaceutical manufacturing site in Kawagoe, close to Tokyo, Japan. Adragos Pharma will also enter into a long-term supply agreement with Sanofi K.K, thereby becoming a strategic partner for Sanofi in the Japanese market. Furthermore, Adragos Pharma will introduce new customers to the manufacturing site from Europe, North America as well as the domestic Japanese market. Their second investment in the region, Adragos Pharma will now rank among the Top 3 largest pure-play CDMOs in Japan. Sanofi and Adragos Pharma signed definitive agreements for the transfer of ownership of one of Sanofi’s manufacturing sites in Japan. The site, located in Kawagoe, Japan, has more than 50 years of pharmaceutical manufacturing history. Under Sanofi, the site ma